[PDF] Top 20 Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

... m 2 according to Japanese estimation equation [27]) during screening, washout or run-in; gastrointestinal surger- ies that induce chronic malabsorption; treatment with insu- lin, glucagon-like peptide-1 ... See full document

... the placebo group (0.13 ± 0.08 %) at week 16 [last observation carried forward ...the placebo group, canagliflozin signifi‑ cantly decreased fasting plasma glucose levels ( − ...blood ... See full document

... blood glucose levels by inhibiting renal glucose re- absorption and increasing urinary excretion of excess glucose ...of type 2 diabetes, including canagliflozin in the US, ... See full document

... of type 2 diabetes mellitus and hypercholesterolemia aged 20 to 75 years were selected to participate in the trial, including those undergoing treatment with oral anti-diabetic drugs or ... See full document

... multicentric, double-blind, placebo-controlled, parallel- group, Phase III, randomized control trial was conducted to evaluate the efficacy and safety of teneligliptin in combina- tion ... See full document

... both type 2 and type 1 ...trochlear. Patients with diabetic opthalmoplegia present with unilateral pain, ptosis, and diplopia with sparing of pupillary ... See full document

... of diabetes, age of the patients and presence of hypertension and other complications including autonomic neuropathy and renal dysfunction may have impacted these results and hence ...“Legacy Effect” ... See full document

... in 2 patients in the exenatide ...to week 10 elevations in amylase levels did not reach significance in any of the groups, and no cases of pancreatitis were ...the study due to ... See full document

... Abstract: Patients with diabetes mellitus are at increased risk from cardiovascular-related morbidity and mortality as compared with healthy ...the postprandial metabolic state and ... See full document

... Obesity represents a chronic disease, and the critical consider- ation during a weight loss intervention is not only the short ‐ medium – term weight loss (3 ‐ 6 months) but also longer ‐ term maintenance of weight loss ... See full document

... our study showed sig- ni fi cant improvements in BMI, WHR, and fasting glucose, their study only reported a potential, albeit non-signi fi cant, downward trend in these ...earlier randomized, ... See full document

... in patients who are at risk of volume depletion, hypotension, and electrolyte ...in patients with moder- ate to severe renal impairment is not recommended by the Committee for Medicinal Products for Human ... See full document

... adverse effect on reproductive performance and lactating indices up to a dose of 1 ...carcinogenicity study in Wistar rats, followed by a mechanical study in non-human primates employing molecular ... See full document

... The intervention group received dietary commands written forms including 10 items (TPM based nutritional recommendations) with each item being explained in detail to every patient by the researcher (Table 1). This ... See full document

... JN is a 59-year-old woman with T2DM diagnosed in 1998, hypertension, hyperlipidemia, and asthma. She was initially treated with metformin and lifestyle modification and was switched to insulin ~ 5 years ago. She is ... See full document

... for placebo (P , 0.05). Patients receiving drug were more likely to have a spontaneous bowel movement within the first 24 hours ...for placebo (P = ...of patients who reported a ... See full document

... Although we conducted a comprehensive systematic review of RCTs of SGLT2 inhibitors, there are still limita- tions to be considered when interpreting our findings. First, our review focused on select adverse events and ... See full document

... for patients with type 2 diabetes mellitus (T2DM) ...present study proposes to test the hypothesis that probiotics will alter the gut microbiota sufficiently to reduce systemic ... See full document

... competing for nutrients, and producing antimicrobial substances [19,20]. Furthermore, they adhere to the gastrointestinal mucosa and are thought to prevent bac- terial translocation from the gut [21]. The strongest evi- ... See full document

... in patients with type 2 ...treating type 2 diabetes and metabolic ...in patients with mild hyperlipidemia, as well as for patients who do not tolerate statins or do ... See full document